Exclusive interviews with industry leaders

  • Charlotte Owens, vice president, head of the Center for Health Equity and Patient Affairs, Takeda
    Image attribution tooltip
    Permission granted by Takeda

    Takeda’s global quest for health equity

    Takeda’s Center for Health Equity and Patient Affairs is built to address health inequality around the world and aims to raise the bar for the pharma industry.

    Taren Grom • Dec. 8, 2022
  • A photograph of a Sarepta building in Boston, MA
    Image attribution tooltip
    Courtesy of Sarepta

    For Duchenne-focused Sarepta, gene therapy is the natural next step

    The company with three marketed RNA drugs for Duchenne muscular dystrophy is taking the logical leap into gene therapies with a candidate under review at the FDA.

    Michael Gibney • Dec. 8, 2022
  • Bill Mezzanotte headshot
    Image attribution tooltip
    Permission granted by CSL

    A historic approval could transform CSL from being ‘the biggest company no one has ever heard of’

    The company’s head of R&D on its profile-raising FDA approval of a gene therapy that’s now the world’s most expensive drug. 

    Meagan Parrish • Dec. 6, 2022
  • Overhead view of a person holding two white pills in their left hand and a glass of water in their right hand.
    Image attribution tooltip
    Stock via Getty Images

    Non-toxic and addiction free: The promise of a new pain med

    Why South Rampart Pharma’s novel new molecule could be a key to solving the global pain epidemic.

    Taren Grom • Dec. 1, 2022
  • Skin
    Image attribution tooltip
    Ivan Balvan via Getty Images

    Evommune’s unique method of drug discovery is more than skin deep

    The biotech is using human skin squares from plastic surgery to find the best immunological molecules for solving conditions like dermatitis.

    Michael Gibney • Nov. 29, 2022
  • lab tubes
    Image attribution tooltip
    Stock via Getty Images

    In cancers with very low survival rates, Sellas aims higher

    The company hopes its drugs can “take over where other available treatments fail” in multiple types of cancer.

    Kelly Bilodeau • Nov. 21, 2022
  • Glen de Vries blue origin
    Image attribution tooltip
    Permission granted by Medidata

    The legacy of Glen de Vries: Our last interview with the pioneering entrepreneur

    Recorded just weeks before his passing, our sit-down interview with the legendary medical sciences entrepreneur showcased his passion for pushing the industry toward its next frontier.

    Taren Grom • Nov. 11, 2022
  • Lene Oddershede
    Image attribution tooltip
    Permission granted by Lene Oddershede

    Novo Nordisk’s quantum bet on ‘world changing’ computing

    Behind the pharma giant’s plans to build the first quantum computer by 2034 to accelerate drug development.

    Taren Grom • Nov. 10, 2022
  • Disabilities
    Image attribution tooltip
    Stock via Getty Images

    The other ‘D’ in DE&I

    How companies can work to include people with disabilities into broader equity aims.

    Taren Grom • Nov. 4, 2022
  • tuberculosis scan
    Image attribution tooltip
    Spencer Platt via Getty Images

    Tuberculosis patients haven’t seen new treatments in 40 years – now Merck and Gates MRI have teamed up to change that

    The Bill & Melinda Gates Medical Research Institute’s clinical development leader talks about its new licensing deal with Merck.

    Alexandra Pecci • Nov. 1, 2022
  • Two researchers pipette blue liquid from beaker's to test tubes.
    Image attribution tooltip
    iStock via Getty Images

    The first company to use Nobel-winning click chemistry in humans is on a mission to transform oncology

    Shasqi founder and CEO José Mejía Oneto on how the company’s approach could provide a more effective alternative to ADCs and other emerging cancer therapies.

    Karissa Waddick • Oct. 27, 2022
  • Wearing a black hoodie, Carolyn Bertozzi stands in the forefront with a tan brick building blurred behind.
    Image attribution tooltip
    Justin Sullivan/Staff via Getty Images

    Nobel Prize winner Carolyn Bertozzi on revealing the power of chemistry in drug development

    The Stanford researcher and biotech entrepreneur discusses how click and bioorthogonal chemistry could revolutionize drug development.

    Karissa Waddick • Oct. 26, 2022
  • Ryan Moslin, senior principal scientist, Bristol Myers Squibb
    Image attribution tooltip
    Permission granted by BMS / Ryan Moslin

    He helped discover BMS’s psoriasis pill Sotyktu. Here’s what he has to say about early science in Big Pharma

    Bristol Myers Squibb’s senior principal scientist Ryan Moslin shares why his team was built for success and how they ushered a potential psoriasis blockbuster through discovery.

    Michael Gibney • Oct. 17, 2022
  • Subvariant virus spreading as viral pathogens
    Image attribution tooltip
    iStock via Getty Images

    Coming out of stealth, RIGImmune aims to catch up with ever-mutating viruses

    President Susan Sobolov discusses how the startup is building on the work of two powerhouse Yale scientists to advance candidates for viruses — and beyond.

    Kelly Bilodeau • Oct. 13, 2022
  • Ameet Mallik horizontal
    Image attribution tooltip
    Permission granted by Ameet Mallik

    Where the CEO of ADC Therapeutics sees ‘huge potential’ in the tech beyond oncology

    The “magic bullet” approach of ADCs has been a breakthrough in cancer care — but this excitement could be just the beginning.

    Meagan Parrish • Oct. 12, 2022
  • Young African American biochemist using microscope while working on scientific research in a laboratory. The view is through the glass.
    Image attribution tooltip
    skynesher via Getty Images

    Citius Pharmaceuticals sees golden opportunities in late-stage specialty assets

    CEO Leonard Mazur explains how the company’s hoping to unlock the potential of its varied pipeline.

    Karissa Waddick • Oct. 11, 2022
  • Silhouettes of two people colored in a swirling spectrum of colors. They are against a background of other spectrum colors and shapes.
    Image attribution tooltip
    Stan Eales via Getty Images

    New partnership may give MDMA an edge in the psychedelics space

    While LSD and psilocybin steal the spotlight, drug developers are also exploring MDMA for a wide swath of neurological illnesses. 

    Kelly Bilodeau • Oct. 10, 2022
  • Professional headshot of Erin Duffy
    Image attribution tooltip

    Permission granted by Asia Kepka

    Her antibiotic company failed. Now she’s helping others avoid the same fate.

    The chief of R&D at CARB-X explains why she believes small antibiotics companies can succeed despite market turmoil.

    Karissa Waddick • Oct. 6, 2022
  • cell therapy infusion
    Image attribution tooltip
    Stock via Getty Images

    It’s electric — speeding up the cell therapy process for scalability

    To improve the development of cell therapy-based treatments, many companies are turning to a technology that uses electric fields.

    Alexandra Pecci • Oct. 4, 2022
  • digital clinical trials
    Image attribution tooltip
    Stock via Getty Images

    Clinical trials haven’t harnessed the digital revolution — TransCelerate’s latest initiative aims to change that

    The nonprofit’s VP of portfolio management discussed its “most transformative” digital initiative to date.

    PharmaVoice staff • Oct. 3, 2022
  • Merck sign
    Image attribution tooltip
    Marko Georgiev / Stringer via Getty Images

    Keytruda is the gift that keeps on giving for Merck, and here’s what’s next for the cancer juggernaut

    Long-term results showed five-year survival numbers for lung cancer patients that surpassed all others, and Merck's VP of oncology research tells us what he's excited about.

    Michael Gibney • Oct. 3, 2022
  • magic mushroom
    Image attribution tooltip
    Stock via Getty Images

    Compass has the most advanced psychedelic drug in trials — but it needs a new approach to rollout to make it a success

    The company's CEO, Kabir Nath, discusses potential roadblocks to commecialization that await its psilocybin treatment for depression. 

    Meagan Parrish • Sept. 27, 2022
  • Autism stock
    Image attribution tooltip
    Stock via Getty Images

    Why precision medicine could be the next frontier in treating autism

    Swiss-based Stalicla is banking on an AI-driven precision medicine discovery platform to deliver needed therapies in the autism space.

    Kelly Bilodeau • Sept. 27, 2022
  • Mobile phone medical doctor
    Image attribution tooltip
    NanoStockk via Getty Images

    That’s not Angry Birds — that’s your doctor learning about novel drugs through gaming

    How pharma companies can teach physicians about mechanism of action and other medication lessons with interactive mobile games.

    Alexandra Pecci • Sept. 26, 2022
  • Brian Goff stands laughing in the forefront, with a crowded room of business attire-clad people in the background.
    Image attribution tooltip

    Permission granted by Brian Goff. 

    First 90 Days: Agios Pharmaceuticals’ Brian Goff

    The rare disease veteran and first-time CEO is bringing his expertise to the company as it launches the first FDA-approved treatment for pyruvate kinase (PK) deficiency.

    Alexandra Pecci • Aug. 22, 2022